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Abstract
Objective: To evaluate the results of screening and diagnostic mammography in a geographically defined population
attending a regional mastology referral hospital of the State Public Service of Sa˜o Paulo.
Methods: A total of 7508 women, who received screening or diagnostic mammography examinations from 06/2004 to 06/
2005, with follow-up until 06/2006, were included in this study. Data corresponding to age, the Breast Imaging-Reporting
and Data System (BI-RADS), biopsy, surgery and the stage of breast cancer were collected. Five-year survival of patients with
breast cancer was posteriorly calculated during this period.
Results: This study included a total of 713 diagnostic and 6795 screening mammograms. The average age of the population
was 51.2 years, with a BI-RADS end result of 4 and 5 (abnormal) in 1.9% of the screening and 11.4% of the diagnostic
mammograms, respectively. All BI-RADS category zero was complemented. Of the 228 nonsurgical biopsies performed (71
CNB, 94 mammotomy and 63 FNAB), 63 (27.6%) biopsies were malignant findings. Among the 33 surgical biopsies, 10
(30.3%) biopsies were malignant findings, and of the 82 surgeries, 55 (67, 1%) procedures showed malignant findings.
Seventy-one (0.9%) breast cancers (25/6795 on screening exams and 46/713 on diagnostics) were diagnosed. A total of
28.6% small cancers (#10 mm) were observed, with 27% of the cancers in stages zero and I. Approximately 47.6% of the
cases showed nodal invasion, and 4.5% of cases were not staged. Overall detection rate of breast cancer was 8.8/1000 (3.2/
1000 screening and 61.7/1000 diagnostic). The overall 5-year survival rate of patients with breast cancer in this population
was 79.1%.
Conclusion: Survival is a key index of the overall effectiveness of health services in the management of patients with cancer.
Our results suggest that this approach is feasible and can potentially improve breast cancer outcomes for many women in
Sa˜o Paulo.
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Introduction
Breast cancer is one of the leading causes of death worldwide,
remaining the second most common type of cancer among
women, with the highest mortality rate among all cancers in
America and western North America. In Canada and the United
States, the statistics show that one in ten women will develop
cancer during her lifetime [1,2]. As the second most prevalent
cancer worldwide and the most common cancer among women,
breast cancer accounts for 22% of new cases each year. If
diagnosed and treated early, the prognosis is more favorable [1,2].
In general, incidence rates are high in Western and Northern
Europe, Australia/New Zealand, and North America, while
intermediate rates have been observed in South America, the
Caribbean, and Northern Africa, and low rates occur in sub-
Saharan Africa and Asia. The factors that contribute to the
international variation in incidence rates reflect differences in
reproductive and hormonal factors and the availability of early
detection services. Reproductive factors that increase the risk of
breast cancer include a long menstrual history, nulliparity, recent
use of postmenopausal hormone therapy or oral contraceptives,
and late age at first birth. Alcohol consumption also increases the
risk of breast cancer [2].
Even if relatively rare before age 35, the incidence of breast
cancer increases rapidly and progressively above this age group.
Statistics show an increased frequency in both developed and
developing countries. According to the World Health Organiza-
tion (WHO), in the 60’s and 70’s a ten-fold increase in age-
adjusted incidence rates was recorded in population-based cancer
registries from different continents [1,2].
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In Brazil, the mortality rates for breast cancer remain high,
potentially reflecting disease diagnosis at advanced stages. In the
world population, the average 5-year survival rate is 61% [1].
In Sa˜o Paulo, the presumed prevalence of suspected and highly
suspected breast cancer lesions from mammograms was 0.615% in
2002 [3].
World screening projects were established approximately 40
years ago, with variations in the age of patients and the screening
approach used. The results of these programs reflect a significant
reduction of mortality from breast cancer [4–6].
Tabar et al. confirmed a reduction of 31% in mortality from
breast cancer and a 25% reduction in stage II or more advanced
cancer diagnoses, reflecting the introduction of a mass screening
program in Sweden in 1977 [7]. Currently, the screening program
of the American College of Radiology (ACR) recommends annual
mammography in patients older than 40 years [8]. In patients less
than 40 years of age, mammography is recommended either when
the patients are considered high risk for developing the disease or
to investigate a palpable breast mass [6,9].
After the introduction of mammography screening programs, a
reduction of 25–35% in mortality from breast cancer in women
from 50 to 74 years of age and a 10–18% reduction in women
from 40 to 49 years of age were observed [10,11]. In April 2004,
screening mammography was established in Brazil for women
between 50 and 69 years of age, with a maximum two-year
interval between examinations [1].
The BI-RADS system was applied to classify breast lesions. In
1992, the American College of Radiology (ACR) and the Brazilian
Society of Mastology (SBM) developed this system to standardize
mammographic reports. Since 1998, this system has been used in
Brazil, according to the guidelines of the Brazilian College of
Radiology (CBR) and the Brazilian Federation of Gynecology and
Obstetrics (FEBRASGO). Thus, assessing the effectiveness of the
use of the BI-RADS system is important for the early detection of
breast cancer.
In April 2004, the Breast Health Program of the Northern
Region in the General Hospital in Vila Nova Cachoeirinha
(HGVNC) "Dr A´lvaro de Souza Simo˜es" was initiated through the
State Health Department of Sa˜o Paulo to provide a specialized
reference for breast diseases, regarding the diagnosis, treatment,
rehabilitation and follow-up of a target population. This popula-
tion, including Basic Health Units in Sa˜o Paulo districts of Vila
Nova Cachoeirinha, Brasilaˆndia, Freguesia de O´, Casa Verde and
Lima˜o, comprised 29 units referred to the program based on the
condition that each unit followed the established protocols
between HGVNC (Referral Hospital) and the referred basic
health units. A protocol was created for the participating patients
with and without symptoms; specific lessons were administered for
the orientation of health professionals of the region and talks were
held to raise the awareness of the local population.
In the HGNVC diagnostic mammography service, only the
districts of Freguesia do O´ and Brasilaˆndia were assisted, resulting
in a total target population of approximately 58,467 women over
40 years (census from 2000).
Considering these aspects, it can be inferred that the HGVNC
presents a regionalized and specialized service for breast health,
intended for a geographically defined population of the city of Sa˜o
Paulo. Thus, due to the lack of epidemiological data concerning
this disease in Brazil, the aim of this study was evaluate this service.
Objectives
The objective of this study was to evaluate the results of
screening and diagnostic mammography in a geographically
defined population of patients from a regionalized mastology
referral hospital of the Public Service of Sa˜o Paulo, using measures
of association, including sensitivity and specificity, positive
predictive values, mammography recall rates, breast cancer
detection rates and the survival study of breast cancer patients
diagnosed during this period.
Methods
Ethics Statement
This study was reviewed and fully approved by the Research
Ethics Committee of the Universidade Federal de Sa˜o Paulo-
Escola Paulista de Medicina (UNIFESP-EPM) (0919/07). The
IRB granted a waiver of written consent due to the retrospective
nature of this study
The Mastology/Breast Imaging Diagnostic service in the
Woman Health Sector of the General Hospital of Vila
Nova Cachoeirinha
In April 2004, the Breast Health Program of the Northern
Region in the General Hospital of Vila Nova Cachoeirinha
(HGVNC) "Dr A´lvaro de Souza Simo˜es" was initiated through the
Department of Health of the State of Sa˜o Paulo to provide a
specialized reference for breast diseases, regarding the diagnosis,
treatment, rehabilitation and follow-up of a target population of
Basic Health Units in Sa˜o Paulo, from the districts of Vila Nova
Cachoeirinha, Brasilaˆndia, Freguesia de O´, Casa Verde and
Lima˜o, comprising a total 29 units referred to the program,
meeting the established protocols of the HGVNC (Referral
Hospital) and the referred basic health units. A protocol was
created for treating symptomatic and asymptomatic patients;
specific talks were held to increase the awareness of the local
population and lessons were administered for the orientation of
health professionals of the region.
In the case of HGNVC diagnostic mammography service, only
the districts of Freguesia do O´ and Brasilaˆndia were assisted,
totaling a target population of approximately 58,467 women over
40 years (2000-IBGE census).
The patients attended the referenced Basic Health Units (BHU)
(Freguesia do O´ and Brasilandia) and were referred to the
Department of Diagnostic Imaging Breast of the HGVNC to
perform mammography. The symptomatic patients were referred
directly to the Department of Mastology at the hospital before
performing the mammography.
A multidisciplinary team (breast oncologists and radiologists)
determined the protocol for obtaining a positive diagnostic
mammography (routine follow-up or surgery).
In tests with benign lesions (BI-RADS categories 1 and 2),
routine examinations were suggested, and the patients were
referred for care at the initial Basic Health Unit. In patients with
benign findings (BI-RADS category 3), follow-up was suggested at
6, 12 and 24 months; the patients were monitored in the Basic
Health Unit. In cases where the patients had a family history (first
degree relatives), a biopsy was recommended. The suspected cases
(BI-RADS categories 4 and 5) were referred to the Ambulatory
Center of Radiology-Mastology Resolution and Integration to
undergo procedures for definitive diagnosis. When the outcome of
these exams was benign, the patients were discharged with new
references to the Basic Health Unit. When malignancies were
detected, the patients were referred to the Mastology service to
continue the protocols. Suspicious or inconclusive cases after
biopsies continued follow-up in the Mastology service at the
hospital. In inconclusive cases (BI-RADS category zero), comple-
mentary diagnostic exams were encouraged (additional mammog-
raphy or ultrasound), returning the patient to the Basic Health
Mammographic Assessment in Sao Paulo Brazil
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Unit and rescheduling complementary exams at the department of
Diagnostic Breast Imaging. In these cases, the attending physician
at the Basic Health Unit performed the complementary exams. In
most of inconclusive cases (BI-RADS category zero), the radiol-
ogist performed exams using bright light radiology, with additional
views, or even ultrasound.
Evaluation of the exams
A team of seven radiologists, with at least 4 years of experience
in breast imaging, analyzed the mammograms. Each exam was
standardized according to the BI-RADS method. [9] These
radiologists also supervised the quality standard of the examina-
tion. In addition, through a weekly program, a specialized team of
technicians developed and fixed the films. Qualified physicists
performed the periodic control of the image quality.
A conventional mammography screening technique, comprising
four mediolateral oblique and craniocaudal views bilaterally, using
a Siemens H Mammomat 3000 equipped with an analog system,
was employed. In some cases, additional images were captured
according to the indication of the present radiologist.
The mammograms were classified as diagnostic (women with
clinical breast complaints) and screening (asymptomatic), accord-
ing to the technical questionnaire collected during the exam.
The positive mammograms were classified as BI-RADS
categories 0 (zero), 4 and 5. All mammograms BI-RADS category
0 (zero) were reclassified after adequate complementation and the
final BI-RADS obtained (additional mammographic or ultrasound
device on Toshiba H Nemio).
In cases requiring investigations through anatomopathological
analysis, the material was obtained using fine-needle aspiration
(FNAB), core-needle biopsy (CNB) or thick-needle vacuum-
assisted biopsy (Mammotome Endo-Surgery Inc. H Johnson and
Johnson company) and submitted to the pathology laboratory,
which specializes in breast cancer. In cases where the material was
inadequate, a second collection was performed. All biopsies were
catalogued for later reference.
Sample population
Inclusion criteria. - Women with positive mammogram (BI-
RADS categories 4 and 5) and cytopathological data were
followed in the service; patients without cytopathological data
were subjected to a mammographic follow-up for a minimum of
24 months;
- Women with a negative test (BI-RADS categories 1, 2 and 3)
were subjected to a mammogram follow-up for 12 consecutive
months.
Exclusion criteria. - Women with no follow-up during the
12 consecutive months after a negative mammogram;
- Women without cytopathological data after positive mam-
mography or without a minimum mammography follow-up for 24
months;
- Mammogram BI-RADS category 6 was excluded (three
exams).
A total of 7508 women who underwent mammography in the
diagnostic imaging service at General Hospital of Vila Nova
Cachoeirinha from June 2004 to June 2005 met the inclusion
criteria for this study. The subjects were obtained from two health
centers (Freguesia de O´ and Brasilaˆndia) of the North Zone of Sa˜o
Paulo (18 UBS), and 1% of the subjects were obtained elsewhere.
These regions are characterized by low socioeconomic status
with high infant mortality (13.65/1,000 live births). A significant
percentage of the inhabitants lived in slums (13.23% versus
11.12% in the city of Sao Paulo), with an annual growth of 3.68%.
The average household income of this population was approxi-
mately $ 390 USD, while in the city of Sao Paulo the average
income is $ 663 USD, with a high prevalence of people under 40
years of age (insert reference here).
Study variables
The variables were obtained through a database service, stored
in "CDI examinations" software, which uses Microsoft Office
Access H, the medical records from patients who underwent
procedures and surgeries and the results of the biopsies performed.
The cancer staging and diagnosis was determined based on the
classification of malignant tumors (TNM), proposed by the
International Union Against Cancer (UICC), according to the
dimensions of the primary tumor, involvement of the lymph nodes
in the lymphatic drainage chain of the breast and the presence or
absence of distant metastases.
The numbers of diagnostic and screening mammography and
their classifications were collected using BI-RADS; true positives
(TP), true negatives (TN), false negatives (FN), false positives (FP),
the total number of cancers in the sample, and the cancer staging
were determined; the biopsies, surgeries and surgical outcomes
were also documented.
Statistical Analysis
The outcome variable of the study was positive for cancer in the
cytological or histopathological samples, fragment biopsies and
surgical specimens.
The statistical analysis was performed using a database in
Microsoft Office ExcelH, and the analyses were performed using
the public domain software Epi Info 7.
The measured parameters and methods to estimate the
performance of the service are described in the auditing section
of the 4th edition of the ACR-BI-RADS (9).
The true-positive exams were defined as exams with a positive
interpretation, followed by the diagnosis of invasive breast
carcinoma or ductal carcinoma in situ within 12 months. The rate
of cancer detection was defined as the number of cancers (positive
exam) divided by the total number of exams. One false positive
was defined as a positive interpretation with no cancer diagnosis
after follow-up.
We calculated the positive predictive value (PPV) by dividing
the number of true positive tests by the total number of tests (true
positive and false positive tests). Three separate PPV were
calculated using the BI-RADS method: PPV1 (probability of
cancer after an examination with initial positive BI-RADS
categories zero, 4 and 5), PPV2 (probability of cancer, followed
by final BI-RADS categories 4 and 5), and PPV3 (probability of
cancer in biopsied patients after final BI-RADS categories 4 and 5,
also known as a positive biopsy rate). For mammograms with an
initial BI-RADS category 0 (zero), the final BI-RADS category was
determined after performing additional images or ultrasound. The
final classification was used to calculate VPP2 and VPP3. The tests
with final BI-RADS categories 4 and 5 were recommended for
biopsies. All biopsy types were included in VPP3 (FNAG, CNB,
mammotomy or surgical biopsies).
False negatives were defined as exams with an initial negative
result (BI-RADS category 1, 2 and 3) and a diagnosis of invasive
breast carcinoma or ductal carcinoma in situ within 12 months.
True negatives were considered as exams with negative initial
interpretations and subsequent negative tests in 12 months.
Simple descriptive statistics were determined (frequency counts,
percentage, mean and median).
During this period, the survival time (in months) of patients
diagnosed with breast cancer was defined as the period between
the date of diagnosis and the last medical consultation or the
Mammographic Assessment in Sao Paulo Brazil
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occurrence of death attributed to breast cancer, according to the
death certificate. At the end of the study, all patients with no
record of death, because they were still alive or died of different
causes, contributed to the follow-up time for the group risk
composition.
The TNM system was used for tumor staging. The tumor size
was grouped into three ranges: less than or equal to 2 cm (T1), 2–
5 cm (T2) and larger than 5 cm (T3). The involvement of lymph
nodes was ranked N0 (no lymph node metastasis), N1 (metastasis
to mobile ipsilateral axillary lymph nodes) and N2 (metastasis to
axillary lymph nodes fixed to one another or structures). Metastasis
was classified as M0 (no distant metastases) or M1 (presence of
distant metastases).
The Kaplan-Meier method was used to estimate the probabil-
ities of survival.
Results
Age groups and BI-RADS
Among the mammographies performed, 713 (9.5%) exams were
diagnostic and 6795 (90.5%) exams were screening mammogra-
phies.
The mean age of the study population was 51.2 years (SD 10.5)
with a median age of 50.5 years, ranging between 15 and 99 years.
In the screening mammography (6795), the average age of the
women was 52.2 years (SD 9.8), with a median age of 50.5 years,
ranging between 36 and 99 years. In the diagnostic mammogra-
phy (713), the average age was 42.2 years (SD 11.8), with a median
age of 38 years, ranging between 15 and 87 years.
Of the 7508 women subjected to mammography, 71 (0.9%)
women had breast cancer, 0.4% (25 of 6795) of these women
underwent screening mammographies and 6.5% (46 of 713) of
these women were subjected to diagnostic mammographies.
In the entire population, the final BI-RADS classification
(Figure 1) included 6905 (92%) benign findings (BI-RADS
categories 1 and 2), 396 (5.3%) potentially benign cases (BI-
RADS category 3) and 207 ( 2.7%) suspicious and highly
suspicious findings (BI-RADS categories 4 and 5).
In the screening mammography (6795), the final BI-RADS
classification included 6407 (94.3%) benign findings (BI-RADS
categories 1 and 2), 262 (3.9%) potentially benign cases (BI-RADS
category 3) and 126 (1.8%) suspicious and highly suspicious
findings (BI-RADS categories 4 and 5).
In the diagnostic mammography (713), the final BI-RADS
classification included 498 (69.8%) benign findings (BI-RADS
categories 1 and 2), 134 (18.8%) potentially benign cases (BI-
RADS category 3) and 81 (11.4%) suspicious and highly suspicious
findings (BI-RADS categories 4 and 5).
According to the initial mammography, 534 (466 screening and
68 diagnostic) of the 7508 women (7.1%) were classified as BI-
RADS category 0 (zero), and these individuals were reclassified
after complementation with additional mammographic views and/
or ultrasound exams. Of these 534 patients, 455 cases (416
diagnostic screening and 39) (85.2%) were reclassified as BI-RADS
categories 1 and 2, 72 cases (46 and 26 diagnostic screening)
(13.5%) were classified as BI-RADS category 3 and 7 cases (4
screening and 3 diagnostic) (1.3%) were classified as BI-RADS
categories 4 and 5.
Family history
A total of 65 cases (0.9%) had a positive family history (first
degree relatives), 0.8% cases (51 of 6795) were subjected to
screening mammography and 2.0% cases (14 of 713) underwent
diagnostic exams.
Biopsies
Regarding the non-surgical biopsies in the screening exams, 19
CNB, 40 FNAB, 5 ultrasound and 72 stereotactic-guided
mammotome procedures were performed. Among these proce-
dures, three women had more than one procedure performed at
the same facility, and only one individual received malignancy
confirmation. This same patient had a final BI-RADS category 5
mammography and opted for treatment at another facility.
Of the diagnostic mammographies, 52 CNB, 23 FNAB and 17
guided mammotome procedures were performed. Among these
procedures, seven women underwent more than one procedure at
the same facility, and six women obtained malignancy confirma-
tions.
A total of 63 FNAB were performed; 40 tests (63.5%) were
screening exams, and only three tests (7.5%) were positive for
cancer. In another 23 (36.5%) diagnostic exams, six (26.09%) tests
were positive for cancer, one (4.35%) test was a pre-malignant
finding and 16 (69.57%) tests were benign findings.
In total, 71 BAGs were performed, 19 BAGS (26.8%) were
screening exams and 52 (73.2%) BAGS were diagnostic tests. In
the screening tests, 11 (57.9%) tests were positive for cancer, one
(5.3%) test was a pre-malignant finding and seven (36.8%) tests
were benign findings. Regarding the diagnostic exams, 36 (69.2%)
exams were positive for cancer and 16 (30.8%) exams were benign
findings.
From the 89 stereotactic-guided mammotome procedures, 72
tests were screening exams and 17 exams were diagnostic tests. In
the screening tests, six cases (8.3%) were positive for cancer, one
case (1.4%) was DCIS, three cases (4.2%) were pre-malignant
findings and 62 cases (86.1%) were benign findings. In the
diagnostic tests, one case (5.9%) was positive for cancer, two cases
(11.8%) were pre-malignant findings and 14 cases (82.4%) were
benign findings.
The five ultrasound-guided mammotomes were all screening
exams. No positive cases were observed, one case (20%) was pre-
malignant and four cases (80%) were benign findings.
Of the 228 non-surgical biopsies (136 in screening tests and 92
in diagnostic) performed in the service (FNAB, CNB and
mammotome), 156 (68.4%) biopsies were benign findings, 63
(27.6%) biopsies were malignant findings, 8 (3.5%) biopsies were
pre-malignant findings and one (0.5%) biopsy was DCIS (in situ
ductal carcinoma).
Figure 1. Final BI-RADS distribution (%). Red – screening; Green –
diagnostic; Blue – total.
doi:10.1371/journal.pone.0074270.g001
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A total of 162 women with final BI-RADS categories 4 and 5
were subjected to nonsurgical biopsies (96 screening and 66
diagnostic), 51 cases (31.5%) were malignant findings, 102 cases
(63%) were benign findings, 8 cases pre-malignant (4.9%) and one
case (0.6%) was DCIS (Table 1).
Of the 77 surgeries performed on women with final BI-RADS
categories 4 and 5 (28 screening and 49 diagnostic tests), 33
(42.9%) procedures were surgical biopsies (16 screening and 17
diagnostic tests). Of these biopsies, 14 (42.4%) cases had confirmed
malignancy and, among these, four cases (12.1%) were ductal
carcinoma in situ (Table 1).
Surgeries
When evaluating the anatomopathological results from surger-
ies from a total of 82 surgeries (31 screening exams and 51
diagnostic exams), 55 (67.1%) procedures were malignant findings,
six (7.3%) procedures were DCIS, five (6.1%) procedures were
pre-malignant findings (atypical ductal hyperplasia and lobular
carcinoma in situ) and 16 (19.5%) procedures were benign findings
(Table 1).
Positive cases (BI-RADS 4 and 5) without surgery or
biopsy
Cases with final positive BI-RADS were not biopsied, and we
opted for early mammographic follow-up. A total of 18 cases
(8.7%) were obtained, 13 of these cases were (72.2%) stable
screening exams during the 2 years of follow-up, and five (27.8%)
cases were diagnostic tests. Of these diagnostic tests, four (BI-
RADS category 4A) exams were stable after two years and one
exam was classified as BI-RADS category 5 (by palpable focal
asymmetry) at early follow-up, revealing a reduction in the
dimensions of these cancers. After collecting the details of this last
case, we observed that the patient had undergone the first
examination during the premenstrual period.
A total of 19 additional cases with BI-RADS categories 4 and 5
(9.2%) were not followed in the service. Of these, 12 (63.2%) cases
were screening tests and seven (36.8%) were diagnostic tests. The
patients were examined, but the contact with ten of these patients
was not possible (these individuals could not be contacted at the
phone number provided). Among the contacted individuals, 2
patients underwent treatment at another facility, four patients
reported benign biopsies collected at another hospital, one (1)
individual refused treatment after the diagnosis of breast cancer
and one individual died of unknown causes (not informed by
relatives) before the initiation of the procedures.
Association measures
In the true-positives exams (TP), 29 (44%) individuals were
affected in the right breast, 35 (53%) individuals were affected in
the left breast and two (3%) patients were affected in both breasts.
In the 66 true-positive cases (TP), the cancer detection rate was
8.8 per 1000 cases. In the screening exams, 22 cases were TP and
the detection rate was 3.2 cancers per 1000 cases. In diagnostic
exams, 44 cases were TP, and the cancer detection rate was 61.7
in 1000 cases (Table 2).
Of the cancers diagnosed and treated at the service, seven
(11.1%) were DCIS, and 56 (88.9%) were invasive carcinomas.
Three cases of cancer were not followed at the service.
In the screening exams (n = 21), six (28.6%) cases were DCIS
and 15 (71.4%) cases were invasive carcinomas. In diagnostic tests,
one case (2.4%) was DCIS and 41 (97.6%) cases were invasive
carcinomas. Four cases of breast cancer were not followed at the
service: the results for three of these cases were not assigned by
patients and in the other case, the patient refused treatment. These
four cases had initial negative mammograms.
The global recall rate was 9.7% (730 of 7508). The PPV1
(percentage of cancer after positive mammogram with BI-RADS
categories zero, 4 and 5) was 9% (66 of 730), PPV2 (percentage of
cancers determined by screening exams with final BI-RADS
categories 4 and 5) was 31.9% (66 of 207), and PPV3 (percentage
of cancers after biopsy of cases with BI-RADS categories 4 and 5
and positive biopsy rates) was 37.7% (66 of 175) (Table 3).
In screening tests, the recall rate was 8.6% (586 of 6795). The
PPV1 was 3.8% (22 of 586), the PPV2 was 17.5% (22 of 126) and
PPV3 was 21.6% (22 of 102) (Table 2).
Table 1. Biopsy distribution and surgery results.
Screening (%) Diagnostic (%) Total (%)
Non-surgical biopsies BI-RADS
categories 4 and 5
Benign 75 (78,1) 27 (40,9) 102 (63,0)
Pre-malignant 5 (5,2) 3 (4,5) 8 (4,9)
Malignant 15 (15,6) 36 (54,5) 51 (31,5)
DCIS 1 (1,1) 0 (0) 1 (0,6)
Surgical biopsies BI-RADS categories 4
and 5
Benign 10 (62,6) 9 (52,9) 19 (57,6)
Malignant 3 (18,7) 7 (41,2) 10 (30,3)
DCIS 3 (18,7) 1 (5,9) 4 (12,1)
Surgeries
Benign 7 (22,6) 9 (17,6) 16 (19,5)
Pre-malignant 4 (12,9) 1 (2,0) 5 (6,1)
Malignant 15 (48,4) 40 (78,4) 55 (67,1)
DCIS 5 (16,1) 1 (2,0) 6 (7,3)
doi:10.1371/journal.pone.0074270.t001
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In diagnostic tests, the recall rate was 20.2% (144 of 713). The
PPV1 was 30.6% (44 of 144), the PPV2 was 54.3% (44 of 81) and
PPV3 was 60.3% (44 of 73) (Tables 4 and 5).
The percentage of all cancers diagnosed as DCIS was 10.6% (7
of 66). Of all invasive cancers with defined dimensions, 17.5% (11
of 63) of these cancers were less than or equal to 10 mm. The
percentage of cancers considered minimal (DCIS and smaller than
10 mm invasive cancers) was 28.6% (18 of 63) (Table 3).
In the screening exams, the percentage of cancers diagnosed as
DCIS was 27.3% (6 of 22). Of all invasive cancers with defined
dimensions, 53.3% (8 of 15) were less than or equal to 10 mm.
The percentage of cancers considered minimal (DCIS and smaller
than 10 mm invasive cancer) was 52.4% (11 of 21). (Table 3)
In the diagnostic exams, the percentage of DCIS in diagnosed
cancers with known histological types was 2.4% (1 of 42). Of all
invasive cancers with defined dimensions, 7.3% (3 of 41) were less
than or equal to 10 mm. The percentage of cancers considered
minimal (DCIS and smaller than 10 mm invasive cancer) was
9.5% (4 of 42). (Table 2)
The cases with nodal invasions were 47.6% in total (30 of 63),
all with known nodal statuses. Of the cancers with known stages,
27% (17 of 63) were classified as stage 0 (zero) and I. The
percentage of cancers with insufficient information to calculate the
staging was 4.5% (3 of 66). (Table 2)
In the screening exams, 23.8% (5 of 21) of the patients showed
nodal invasion, all with known nodal status. Of the cancers with
known stages, 61.9% (13 of 21) were classified as stage 0 (zero) and
I. The percentage of cancers with insufficient information to
calculate the staging was 4.5% (1 of 22). (Table 2)
In the diagnostic exams, 59.5% (25 of 42) of the patients showed
nodal invasion, all with known nodal status. Among the cancers
with known stages, 9.5% (4 of 42) were classified as stage 0 (zero)
and I. The percentage of cancers with insufficient information to
calculate the staging was 4.5% (2 of 44). (Table 2)
The sensitivity and specificity of the mammographies performed
during the specified period were 93% and 98.1%, respectively
(Table 3)
Survival analysis
Among the 71 patients with breast cancer, 67 (94.4%) patients
were followed for a period of five years after diagnosis. Four
patients were not included because they sought treatment at other
facilities and data was not available. The total number of deaths in
the followed cases was 14. There was no statistically significant
predominance of deaths among the cancer staging. Only three
patients remained alive with recurrent cancer, representing 5.7%
of live patients and 60% (3/5) of recurrent cancer cases. The
overall survival rate after five years was 79.1% (Figure 2)
In the present study, we observed that the larger the tumor, the
greater the relative risk of death from breast cancer.
Discussion
This study evaluated the introduction of a pilot program for the
early detection of breast cancer in a defined population.
In Brazil and other developing countries, mammography-
screening programs are primarily opportunistic rather than used
to screen asymptomatic women [11,12]. The Brazilian National
Cancer Institute (INCA) formerly recommended that all women
between 40 and 49 years of age should have clinical breast
examination, and women aged 50 to 69 years should have a
mammogram every 2 years [1]. However, since 2009, federal laws
have made it mandatory for women aged 40 years and older to
receive annual mammograms.
The studies used as the basis for planning the health policies in
Brazil primarily originate from developed countries, where the
health systems and population characteristics are different from
those of Brazil. Thus, we propose that low- and middle-income
countries, such as Brazil, should utilize their own breast cancer
Table 2. Final BI-RADS classification and detected cancer.
Positive Cancer Negative Cancer
Screening Diagnostic Screening Diagnostic Total
Positive mammogram (BI-RADS
categories 4 and 5)
22 44 104 37 207
Negative mammogram (BI-RADS
categories 1, 2 and 3)
3 2 6666 630 7301
Total 25 46 6770 667 7508
P,0,01.
Sensibility - Screening: 88%; Diagnostics: 95,7%; Total: 93%.
Specificity - Screening: 98,5%; Diagnostic: 94,4%; Total: 98,1%.
doi:10.1371/journal.pone.0074270.t002
Table 3. General results from 7508 mammographies.
TP FP1 FP2 FP3
Positive mammogram
(0,4,5) PPV1 PPV2 PPV3 Detection rate Recall rate
Screening 22 564 104 80 586 3,7 17,5 21,6 3,2 8,6
Diagnostic 44 100 37 29 144 30,6 54,3 60,3 61,7 20,2
Total 66 664 141 109 730 9,0 31,9 37,7 8,8 9,7
doi:10.1371/journal.pone.0074270.t003
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Table 4. Cancer detection in the total mammographies evaluated.
Detected cancer characteristics Screening n (%) Diagnostic n (%) Total (7508) n (%)
Tumor type
DCIS 6 (28,6) 1 (2,4) 7 (11,1)
Invasive 15 (71,4) 41 (97,6) 56 (88,9)
Minimal cancer (DCIS and invasive cancer #10 mm) 11 (52,4) 4 (9,5) 18 (28,6)
Nodal invasion
Yes 5 (23,8) 25 (59,52) 30 (47,6)
No 16 (76,2) 17 (40,48) 33 (52,4)
Unknown 1 (4,5) 2 (4,5) 3 (4,5)
Stage*
0 5 (23,8) 1 (2,4) 6 (9,5)
I 8 (38,1) 3 (7,1) 11 (17,5)
II 6 (28,6) 22 (52,4) 28 (44,4)
III 1 (4,8) 12 (28,6) 13 (20,6)
IV 1 (4,8) 4 (9,5) 5 (7,9)
Unknown 1 (4,5) 2 (4,5) 3 (4,5)
Note: The number of all detected cancers was 66 and the detection rate was 8.79 per 1,000.
Screening exams - detected cancers: 22; detection rate of 3.24/1000.
doi:10.1371/journal.pone.0074270.t004
Figure 2. Survival curve (Kaplan-Meier) of the patients in the study.
doi:10.1371/journal.pone.0074270.g002
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data to develop national health policies towards increased efficacy,
e.g. in the breast cancer screening programs.
In this study, we observed that a higher percentage of young
women with breast cancer (40–49 y/o), likely reflecting the high
prevalence of young people in that area. In another study, in the
region of Barretos, SP, Brazil, higher rates of breast cancer in
younger women were also observed, demonstrating the impor-
tance of early mammographic screening in this region [13].
The breast cancer detection rate is associated with the incidence
and prevalence of disease in a population, the characteristics of the
screened population (mean age, breast density, previous exposure
to screening and risk of breast cancer), the characteristics of the
local health system (degree of concern about medico-legal
complaints, financial incentives, and quality control) and the
quality of service [14]. Methodological parameters might also
influence the results reported, such as the inclusion or exclusion of
palpable nodules. The detection rate increases with the age of the
screened population [15-17] and decreases with prior exposure to
screening [18–19].
In this study, we calculated a detection rate of 3.24/1000 in
asymptomatic patients, 61.71 in symptomatic patients and 8.79 in
the total exams. These detection rates were consistent with
previously published studies. Sickles et al. [20] achieved a
detection rate of 25.3/1,000 in symptomatic patients. Keen and
Keen [16] showed a detection rate of 1.9/1000 at age 40, a rate of
7.2/1000 at age 50 and a rate of 15.1/1000 at age 60. Smith-
Bindman et al. [17] compared with the results from three large
screening programs, including two programs in the United States
(BCSC, NBCCEDP) and one program in England (NHSBSP),
analyzing 5.5 million mammograms in patients 50 years or older;
the results showed detection rates of 5.8, 5.9, and 6.3/1000,
respectively. Jiang et al. [16] conducted a multicenter study using
510 radiologists to analyze the results of 2,289,132 screening
mammograms, showing a detection rate of 3.91/1000. The BI-
RADS considers a detection rate between two and ten as desirable.
A rate of six to ten patients has been observed for individuals
undergoing their first mammography, and a rate of two to four
patients for individual who have been previously screened [8].
Sohlich et al. [9] observed that in mixed services (screenings and
diagnoses evaluated together), in a proportion of 90 diagnostic
exams per ten screening exams, the detection rate should be ten.
The current study showed that the proportion of screening/
diagnostic exams resulted in a lower detection rate, potentially
reflecting the large number of patients younger than 50 years.
The positive predictive value indicated in this work was 9.04%
between all mammograms considered as abnormal (PPV1) and
31.88% among the patients who received biopsy indications
(VPP2). The BI-RADS considers a PPV1 of 5–10% and PPV2 of
25–40% as desirable. In a multicenter study, Taplin et al. [20]
reported a PPV1 of 4.1% and PPV2 of 38.8%. Duijm et al. [21]
observed a PPV2 of 37.4%. Rosenberg et al. [22] observed a
PPV1 of 4.8% and a PPV2 of 24.6%. In a Brazilian study,
Azevedo et al. [23] reported a PPV1 of 11% and a PPV2 of 31%.
The recall rate in this study was 9.72% in the total population,
8.62% in the screening population and 20.20% in the diagnostic
population. Other authors reported 14.2 to 15.7% (England) [15],
9.8% (USA) [24] and 2.7% (Norway) [24], 14.4% and 12.5%
(USA) and 7.6% (England) [17]. Schell et al. [25] estimated that
the recall rates leading to optimal results would be 10% in the first
mammogram and 6.7% in subsequent mammograms. The BI-
RADS considers a recall rate of less than 10% as desirable [8].
Variations in the accuracy and results of mammography have
been observed. In Brazil, data concerning the population are
scarce. In June 2009, the SISMAMA [26] was established to
manage breast cancer early detection programs, but the system
remains flawed. In a screening program for breast cancer, the ratio
of invasive carcinoma to carcinoma in situ represents the frequency
of invasive lesions to noninvasive lesions between the identified
cancers. This ratio increases with increasing age, suggesting that
higher ratios are observed in older age groups. In the analyzed
time period, the ratio for all the age groups in SISMAMA was 9.0;
a ration of 2.7 was observed in the present study. This result
confirms that breast cancer is diagnosed late in Brazil.
The BI-RADS showed that more than 30% of cancers
diagnosed in screening exams are minimal (DCIS and invasive
less than 1.0 cm) and more than 50% of the cancers are in the
early stages (zero and I) [8]. In this population sample, we detected
28.6% minimal cancers and 27% of cancers in the early stages.
Considering only screening exams, we detected a significantly
higher detection rate of 53.3% minimal breast cancers and 61.9%
early stage cancers. Compared with other studies [19,27] the rate
of cancers at advanced stages was actually higher (90.5% in this
sample population) in diagnostic tests. Sohlich et al. [9] showed
90:10 in mixed services, indicating a rate of 87%.
The survival rates at 5 years for breast cancer widely varied
between countries. A study published in 2008, reported 5-year
rates of 58.4% for breast cancer in Brazil, 83.7% in the U.S.,
73.1% in Europe and 81.6% in Japan [26]. Studies with patients
treated at INCA-Brazil, showed that breast tumors for the overall
survival rate at five years was 52% [27]. The survival rate of
79.1% observed in this study demonstrates that the introduction of
a screening and diagnostic mammographic service contributes to
an early diagnosis of breast cancer in this population.
There are several limitations that should be addressed in this
study. The lack of demographic data precluding comparisons
between screened and unscreened groups and the impossibility of
monitoring patients that might present different registration
numbers at each service, thereby requiring the manual manage-
ment of this problem for collecting these data. Failures in the
Unified Health System in Brazil (UHS) were also observed,
making it difficult to collect adequate epidemiological data. In
addition, our analyses only controlled for age and tumor stage at
diagnosis because data were not available for other potential
prognostic factors, such as comorbid diseases. Moreover, most of
Brazilian programs are opportunistic, and some authors have
reported low attendance rates in their programs [11].
Conclusions
The evaluation of the breast cancer screenings and diagnostic
programs in a geographically defined population at Sa˜o Paulo
does not clarify the complex issues associated with the epidemi-
ology of breast cancer in Brazil. Many challenges still remain, but
the data obtained in this study provide considerable information to
guide future efforts. Survival is a key index of the overall
effectiveness of health services in the management of patients
with cancer. Our results suggest that a screening and diagnostic
program is feasible and can potentially improve breast cancer
outcomes for many women in Sa˜o Paulo. We propose that these
data will also contribute to the development of similar programs in
other areas of Brazil and other developing countries with similar
socioeconomic statuses.
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